State Street Corp reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 536,367 shares of the medical research company’s stock after selling 1,951 shares during the period. State Street Corp owned about 1.81% of Bio-Rad Laboratories worth $106,924,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Creative Planning increased its position in shares of Bio-Rad Laboratories by 3.2% in the first quarter. Creative Planning now owns 1,080 shares of the medical research company’s stock valued at $215,000 after buying an additional 33 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Bio-Rad Laboratories by 6.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,020 shares of the medical research company’s stock worth $176,000 after buying an additional 65 shares in the last quarter. Two Sigma Investments LP increased its stake in Bio-Rad Laboratories by 0.9% in the fourth quarter. Two Sigma Investments LP now owns 9,781 shares of the medical research company’s stock worth $1,783,000 after buying an additional 87 shares in the last quarter. Flinton Capital Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after buying an additional 96 shares in the last quarter. Finally, Amalgamated Bank increased its stake in Bio-Rad Laboratories by 3.0% in the first quarter. Amalgamated Bank now owns 3,288 shares of the medical research company’s stock worth $655,000 after buying an additional 96 shares in the last quarter. 63.89% of the stock is owned by hedge funds and other institutional investors.
Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) traded down 0.96% during trading on Friday, reaching $231.59. The company’s stock had a trading volume of 114,399 shares. The firm has a market cap of $6.86 billion, a P/E ratio of 245.85 and a beta of 0.91. The stock’s 50 day moving average is $226.46 and its 200 day moving average is $207.68. Bio-Rad Laboratories, Inc. has a one year low of $142.06 and a one year high of $238.00.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a return on equity of 3.23% and a net margin of 1.35%. The firm had revenue of $500.05 million during the quarter, compared to analyst estimates of $477.76 million. During the same quarter in the previous year, the business earned $0.42 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post $2.94 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/07/22/state-street-corp-sells-1951-shares-of-bio-rad-laboratories-inc-nysebio-updated.html.
A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price target on the stock in a report on Monday, May 1st. Jefferies Group LLC restated a “buy” rating and set a $250.00 price target on shares of Bio-Rad Laboratories in a report on Thursday, April 27th. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 target price on the stock. Deutsche Bank AG upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their target price for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. Finally, BidaskClub upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $228.80.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.